Moroctocog alfa
ReFacto (moroctocog alfa) is a protein pharmaceutical. Moroctocog alfa was first approved as Refacto af on 1999-04-13. It has been approved in Europe to treat hemophilia a.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| xyntha | Biologic Licensing Application | 2011-01-13 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
400 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemophilia a | D006467 | EFO_0007267 | D66 | 46 | 38 | 114 | 52 | 121 | 347 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | 5 | 1 | 12 | 3 | 11 | 31 |
| Hemophilia b | D002836 | — | D67 | 2 | 2 | 12 | 2 | 11 | 28 |
| Hemostatic disorders | D020141 | — | — | 4 | 2 | 8 | 3 | 8 | 24 |
| Von willebrand diseases | D014842 | EFO_0003910 | D68.0 | 1 | 2 | 14 | 3 | 3 | 22 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 4 | 3 | 7 | 14 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 1 | 1 | 3 | 2 | 5 | 11 |
| Coagulation protein disorders | D020147 | — | — | 1 | — | 4 | 1 | 4 | 10 |
| Inherited blood coagulation disorders | D025861 | — | — | — | — | 2 | 1 | 5 | 8 |
| Recurrence | D012008 | — | — | — | — | — | 1 | 2 | 3 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhagic disorders | D006474 | — | D69.9 | — | — | 3 | — | 3 | 6 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | — | — | 2 | — | 3 | 5 |
| Type 3 von willebrand disease | D056729 | Orphanet_166096 | D68.03 | 1 | — | 1 | — | 2 | 4 |
| X-linked genetic diseases | D040181 | — | — | — | — | 1 | — | 1 | 2 |
| Bone diseases | D001847 | — | M89.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | 1 | — | — | — | 5 |
| Genetic therapy | D015316 | — | — | 1 | 1 | — | — | 1 | 2 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 1 | — | — | — | 1 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | — | 1 | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | — | — | — | 1 |
| Hemostasis | D006487 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | 1 | — | — | — | 1 | 2 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | — | — | — | — | 1 |
| Factor vii deficiency | D005168 | — | D68.2 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | — | 3 | 3 |
| Sclerosis | D012598 | — | — | — | — | — | — | 3 | 3 |
| Thrombosis | D013927 | — | — | — | — | — | — | 3 | 3 |
| Motor activity | D009043 | EFO_0003940 | — | — | — | — | — | 2 | 2 |
| Postpartum hemorrhage | D006473 | — | O72 | — | — | — | — | 2 | 2 |
| Infertility | D007246 | EFO_0000545 | — | — | — | — | — | 2 | 2 |
| Pregnancy complications | D011248 | — | — | — | — | — | — | 2 | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
| Seroma | D049291 | — | — | — | — | — | — | 1 | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | — | — | 1 | 1 |
Show 43 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Moroctocog alfa |
| INN | moroctocog alfa |
| Description | Moroctocog alfa (trade name ReFacto in the EU) is a recombinant antihemophilic factor genetically engineered from Chinese hamster ovary (CHO) cell line. Chemically it is a glycoprotein. It is manufactured by Genetics Institute, Inc. and used to control and prevent hemorrhagic bleeding and prophylaxis associated with surgery or to reduce the number of spontaneous bleeding episodes in patients with hemophilia A. It is partially a recombinant coagulation factor VIII since it has an amino acid sequence which compares to the 90 + 80 kDa form of factor VIII (BDDrFVIII). It also has posttranslational modifications which are similar to those of the plasma-derived molecule. It can not prevent hemorrhagic bleeding associated with von Willebrand's disease since it is not a von Willebrand factor.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109137 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB13999 |
| UNII ID | 113E3Z3CJJ (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Refacto – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 454 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,295 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use